XML 66 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Reconciliation of Segment Information to Total Consolidated Information
Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.
(In millions)
 Generics Segment
 
Specialty Segment
 
Corporate /
Other(1)
 
Consolidated
Three Months Ended September 30, 2016
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
2,625.0

 
$
432.1

 
$
—

 
$
3,057.1

Intersegment
27.4

 
7.2

 
(34.6
)
 
—

Total
$
2,652.4

 
$
439.3

 
$
(34.6
)
 
$
3,057.1

 
 
 
 
 
 
 
 
Segment profitability (loss)
$
799.3

 
$
278.2

 
$
(1,208.2
)
 
$
(130.7
)
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2016
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
6,709.4

 
$
1,099.7

 
$
—

 
$
7,809.1

Intersegment
29.5

 
13.7

 
(43.2
)
 
—

Total
$
6,738.9

 
$
1,113.4

 
$
(43.2
)
 
$
7,809.1

 
 
 
 
 
 
 
 
Segment profitability
$
1,923.7

 
$
658.3

 
$
(2,196.2
)
 
$
385.8

(In millions)
 Generics Segment
 
Specialty Segment
 
Corporate /
Other(1)
 
Consolidated
Three Months Ended September 30, 2015
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
2,249.9

 
$
445.3

 
$
—

 
$
2,695.2

Intersegment
1.4

 
1.2

 
(2.6
)
 
—

Total
$
2,251.3

 
$
446.5

 
$
(2.6
)
 
$
2,695.2

 
 
 
 
 
 
 
 
 
Segment profitability
$
788.5

 
$
258.2

 
$
(445.6
)
 
$
601.1

 
 
 
 
 
 
 
 
 
Nine Months Ended September 30, 2015
 
 
 
 
 
 
 
Total revenues
 
 
 
 
 
 
 
Third party
$
5,968.8

 
$
969.8

 
$
—

 
$
6,938.6

Intersegment
5.2

 
5.8

 
(11.0
)
 
—

Total
$
5,974.0

 
$
975.6

 
$
(11.0
)
 
$
6,938.6

 
 
 
 
 
 
 
 
 
Segment profitability
$
1,834.0

 
$
524.2

 
$
(1,321.2
)
 
$
1,037.0

____________
(1) 
Includes certain corporate general and administrative and R&D expenses; litigation settlements and other contingencies, net, which for the three and nine months ended September 30, 2016 included the Medicaid Drug Rebate Program Settlement and the Strides Settlement, as discussed further in Note 18 Contingencies; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.